DJIA 18,214.42 -10.15 -0.06%
NASDAQ 4,987.89 20.75 0.42%
S&P 500 2,110.74 -3.12 -0.15%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)

104.39 -2.27 (-2.13%)

REAL-TIME: Last trade at

Extended Hours: $104.54 $0.15 (0.14%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

ALNY $104.39 -2.13%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $106.36
Previous Close $106.66
Daily Range $102.38 - $106.90
52-Week Range $47.03 - $111.49
Market Cap $8.7B
P/E Ratio -21.99
Dividend (Yield) $0.00 (0.0%)
Volume 402,986
Average Daily Volume 853,665
Current FY EPS -$2.95

Sector

Healthcare

Industry

Drug Makers

Alnylam Pharmaceuticals (ALNY) Description

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes. Website: http://www.alnylam.com/

News & Commentary Rss Feed

2 Small Biotech Stocks Dreaming Big in Hepatitis C

Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.

Use Options For a Chance To Buy ALNY at a 36% Discount

Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog

Theravance Reports In Line Loss in Q4, Revenues Increase - Analyst Blog

Regeneron Beats on Q4 Earnings Driven by Eylea Sales (revised) - Analyst Blog

Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog

Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog

Company News for February 17, 2015 - Corporate Summary

Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog

Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog

Zacks Rank #1 Additions for Friday - Tale of the Tape

Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog

See More ALNY News...

ALNY's Top Competitors

ALNY $104.39 (-2.13%)
Current stock: ALNY
AMGN $158.97 (0.56%)
Current stock: AMGN
GILD $104.19 (-0.23%)
Current stock: GILD
BIIB $410.10 (0.28%)
Current stock: BIIB